Motoki Matsuura

Sapporo Medical University, Sapporo, Hokkaidō, Japan

Are you Motoki Matsuura?

Claim your profile

Publications (16)14.68 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Chemotherapy-induced nausea and vomiting (CINV) can affect a patient's quality of life, leading to poor compliance with further treatments. Previous studies have provided minimal data about carboplatin-based regimens. Female sex is a known risk factor for CINV. The purpose of this study was to evaluate palonosetron plus single-dose dexamethasone (DEX) for preventing CINV caused by carboplatin plus paclitaxel combination therapy (TC regimen) in patients with gynecologic cancers. Patients were recruited for this phase-II, multicenter, randomized trial from 12 hospitals in Hokkaido, Japan. Eligible patients were women with uterine cervical, endometrial or ovarian cancer scheduled to receive conventional TC regimen or dose-dense TC regimen; 116 patients were randomly assigned to receive palonosetron in combination with 1-day DEX or 3-day DEX. During the overall period, complete response (CR) was observed in 67.9% (95% confidence interval, 53.7-80.1) of patients in the 3-day DEX arm, and 60.7% (95% confidence interval, 46.8-73.5) of patients in the 1-day DEX arm; CR was significantly lower in the 1-day DEX arm if motion sickness was already present (P = 0.0370). In the severe hyperemesis gravidarum cohort, CR in the 1-day DEX arm tended to be lower than in the 3-day DEX arm. Combination therapy of palonosetron and 1-day DEX was effective for subjects undergoing a TC regimen for gynecologic cancers. However, the possibility of reduced efficacy of 1-day only DEX therapy in women undergoing a TC regimen could not be refuted and requires further investigation. © 2015 Japan Society of Obstetrics and Gynecology.
    Journal of Obstetrics and Gynaecology Research 07/2015; DOI:10.1111/jog.12748 · 0.93 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Intravenous leiomyomatosis( IVL) is a benign tumor that originates from a uterine myoma and rarely extends to the heart through the inferior vena cava (IVC). Echocardiography revealed an abnormal mass in the right atrium in a 63-year-old asymptomatic woman. Preoperative examination revealed a tumor extending from a myoma through the right internal iliac vein to the right atrium, and the patient was diagnosed with IVL. She underwent sternotomy combined with laparotomy, and the intravenous and intracardiac tumor was removed under normothermic cardiopulmonary bypass without cardiac arrest. Hysterectomy and bilateral adnexectomy were also performed. No additional therapy was required after surgery.
    Kyobu geka. The Japanese journal of thoracic surgery 03/2015; 68(3):188-91.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract The purpose of this study was to investigate whether apparent diffusion coefficient (ADC) mean values can be used for predicting the treatment response in ovarian endometrial cyst patients with dienogest (DNG) administration. Eighteen patients received DNG (2 mg/day, orally) for 60 days, among whom 26 ovarian endometrial cysts were retrospectively identified. Mean ADC values of individual ovarian endometrial cysts were obtained by ADC maps inside the tumor. There was a significant correlation between ADC values and reduction ratio. When calculating the mean ADC values for three groups; more than 50%, 50-25% and less than 25%, ADC values significantly increased with increasing reduction ratio; 2.05 × 10(-3 )mm(2)/s, 1.28 × 10(-3 )mm(2)/s and 0.94 × 10(-3 )mm(2)/s, respectively (p = 0.0180). Multiple regression analysis by reduction ratio (%), ADC mean values (×10(-3 )mm(2)/s), tumor longest diameter (cm) and CA125 (U/ml) revealed that tumor reduction ratio by DNG administration could be predicted by the following equation; R = 19.3 + 24.0x - 0.4y + 0.1z (R: Reduction ratio, x: ADC mean, y: Longest diameter, z: CA125). In conclusion, the ADC mean value is useful for the prediction of the treatment response in ovarian endometrial cyst patients with DNG administration.
    Gynecological Endocrinology 05/2014; 30(8). DOI:10.3109/09513590.2014.911277 · 1.14 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: 目的 : 子宮頸部細胞診 ASC-US 例に対する HPV の検査はコルポスコープの必要性をはじめとする管理方針を決める際に重要であるため, 臨床背景や転帰を検討した.方法 : 2010 年 1 月∼2011 年 12 月, 子宮頸部細胞診を施行した 12141 例のうち ASC-US と診断され, High Risk HPV の検索を行った例を対象に統計処理し, 検討した.成績 : ASC-US は全体の 1.9%であった. HPV 検査を行った 73 例のうち, 66%が HPV 陽性であった. 組織診では CIN 1 が 25%, CIN 2 以上が 21%に認められた. CIN 1 であった 19 人中 15 人が細胞診陰性化した. CIN 2・3 の 12 人は, 4 人が円錐切除術となり, 残りは経過観察となった. 年齢・経産の有無・喫煙を項目に logistic 解析を行った結果, HPV 陽性であることが病変の進行に関わってくるとことが示唆された. さらに CIN をスコア化し, 年齢や HPV-DNA 検査を項目とした多変量解析を行った結果, ASC-US 例において High Risk HPV 陽性であることが CIN 進行因子となることが示された.結論 : 適切な検体から得られた ASC-US の異形成度は多岐にわたるため, HPV 検査が判断材料となりうる. 今回, 単一施設における検討から ASC-US 例へ HPV 検査を行う重要性を再確認した.
    01/2014; 53(5):362-365. DOI:10.5795/jjscc.53.362
  • Open Journal of Obstetrics and Gynecology 01/2014; 04(10):617-620. DOI:10.4236/ojog.2014.410085
  • 01/2014; 53(2):120-125. DOI:10.5795/jjscc.53.120
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Vaginal adenosis is one of the rare dis-eases of the vagina, and almost all patients are as-ymptomatic. We report a case of spontaneous vaginal adenosis, which caused vesicovaginal fistula. Case Presentation: Our patient was a 25-year-old Japanese woman. She was admitted to our hospital, and her chief complaint was continuous urine flow from the vagina. We found a tumor with a vesicovaginal fistula in her vagina. Subsequent cytological analysis of vaginal smears showed a normal vaginal mucosa. The patient underwent tumor resection and a fistula patch. Pathological diagnosis was adenosis of the vagina, even though the patient had no known history of in-trauterine diethylstilbestrol exposure or Müllerian developmental abnormalities. Conclusion: The clini-cal course of our case was a malignant tumor, which invasively bored a hole in the vaginal wall forming a vesicovaginal fistula, even though it was a benign le-sion. Therefore, overzealous treatment should be avoided in this case.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Combination of anticancer drugs may provide a rational molecular basis for novel chemotherapeutic strategies. Paclitaxel and SN-38 (an active metabolite of CPT-11) are effective for many kinds of cancer. Therefore, we investigated the possibility that combination of these drugs could be effective against cervical adenocarcinoma cells. In this study, we examined cell growth inhibition after 96 h using the MTT assay and examined the release of fragmented DNA into the cytoplasm during apoptotic cell death by PI staining. Single and combined use of paclitaxel and SN-38 produced significant cytolethality against the cervical adenocarcinoma cell line CAC-1. Addition of a low concentration of SN-38 reduced the IC50 value of paclitaxel compared to that without SN-38, although the low concentration of paclitaxel did not enhance the cytotoxicity of SN-38. FACS scan analysis suggested that these drugs induced apoptosis and cell cycle arrest, and that caspase-3 and -7 were activated in the process. MTT assay and the IC50 demonstrated that paclitaxel had strong cytotoxicity against CAC-1 as well as other cancer cells. In this study, though only a single cell line was used for the experiment and the data are limited, our results suggest that paclitaxel together with low-dose CPT-11 is a promising basis for a new combination cancer chemotherapy.
    Medical Molecular Morphology 03/2013; 47(1). DOI:10.1007/s00795-013-0036-x · 1.07 Impact Factor
  • 01/2013; 29(2):443-447. DOI:10.5180/jsgoe.29.443
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the study was to evaluate disease persistence after conization of CIN3 and microinvasive cervical carcinoma. Medical records from a total of 231 patients were reviewed. The prevalence of CIN3 and cervical carcinoma diagnosed by means of conization were analyzed. All conizations were performed under lumbar anesthesia using a laser technique. Of the 231 patients, 25 had margin involvement with CIN3 or microinvasive carcinoma. Among these 25 patients, 10 underwent hysterectomy. Two of these 10 patients had CIN3 and eight had microinvasive carcinoma. Residual disease was observed in hysterectomy specimens from 9 of the 10 patients. Of the eight patients diagnosed with microinvasion from post-cone hysterectomy specimens, four had CIN3 and three had microinvasive carcinoma. The three patients with microinvasion were found to have a larger area of residual disease as compared with other patients with margin involvement. Conization alone seems to be a reasonable treatment for patients with CIN1, 2, 3, and microinvasive carcinoma. For adenocarcinoma, in situ treatment with conization alone is possible but requires careful follow-up. Hysterectomy appears to be a safe treatment option for microinvasive adenocarcinoma, although follow-up by cytology is sometimes possible in cases with negative surgical margins.
    Archives of Gynecology 06/2011; 285(2):453-7. DOI:10.1007/s00404-011-1944-4 · 1.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Poor prognosis in ovarian clear cell carcinoma is associated with the expression of a defined set of proteins including osteopontin (OPN) and integrin. Statins, a family of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors, are currently being investigated for the treatment and prevention of cancer. In this study, we investigated the effects of simvastatin on ovarian clear cell carcinoma (OCCC) cells in vitro and in vivo and elucidated the mechanism of drug action. Changes in OPN gene expression were determined by real-time RT-PCR, and an MTT assay was performed to determine effects on cell proliferation. Finally, a xenograft tumor model was constructed to evaluate the effects of simvastatin on cell proliferation and apoptosis in vivo. According to our experimental results, OPN is an important protein in OCCC. Simvastatin inhibited OCCC cell proliferation, and the inhibition rate was approximately 40% to 50% after treatment with 10 µM simvastatin for 48 h. In the xenograft studies, simvastatin treatment resulted in a significant growth inhibition. Furthermore, the mice treated with simvastatin survived significantly longer compared to the control groups. In conclusion, simvastatin has anticancer effects in vitro and in vivo. Further confirmation of the anticancer effects of statins in future studies will increase the scope for OCCC treatment.
    Oncology Reports 01/2011; 25(1):41-7. DOI:10.3892/or-00001039 · 2.19 Impact Factor
  • Source
    Motoki Matsuura · Takahiro Suzuki · Tsuyoshi Saito
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent studies have demonstrated overexpression of osteopontin (OPN) in ovarian clear cell carcinoma. Here, we revealed the role of OPN in invasiveness in ovarian clear cell carcinoma. We used immunofluorescence analysis to detect OPN in a total of 160 patient-derived specimens. Ovarian clear cell carcinoma cell lines, RMG-1 and TOV-21G, were used to monitor changes in OPN and integrin levels, and cell invasiveness following treatment with OPN, simvastatin, and transfection with siRNA. Immunofluorescence analysis revealed statistically significant differences among the histological groups, and ovarian clear cell carcinoma expressed a strong OPN signal. The OPN receptors, alpha v and 5, and beta 1 and 3 integrins, were increased after treatment with OPN. Invasion assays indicated that OPN enhanced in vitro extracellular matrix invasion dose-dependently in ovarian clear cell carcinoma. Simvastatin significantly reduced expression of OPN and the integrins, and decreased ECM invasion. RNA interference also suppressed ECM invasion. These results suggest that down- or up-regulation of OPN is involved in carcinoma cell invasion. We thus conclude that OPN regulation could have a crucial role in ovarian clear cell carcinoma therapy.
    Cancer Science 08/2010; 101(8):1828-33. DOI:10.1111/j.1349-7006.2010.01615.x · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate usefulness of uterine cervical and endometrial cytology for detecting ovarian cancer and predicting histologic type. Retrospective analysis was performed on uterine cervical and endometrial cytology data on 163 patients with ovarian cancer. Cervical and endometrial abnormalities were detected in 10 and 19 of the patients evaluated. Patients whose cervical and endometrial cytology revealed abnormal cells were classified as having ovarian cancer at International Federation of Gynecology and Obstetrics (FIGO) stages III and IV Peritoneal cytology proved positive in many of the patients with abnormal findings on uterine cytologic analysis. Of the 19 patients with positive uterine cytologic findings, 12 had recurrence of ovarian cancer after radical therapies. Lymph node metastases were detected in 9 of 19 patients. Our findings indicated that it is possible to predict histologic type in ovarian cancer in 90% of cases of positive cervical smears and 79% ofabnormal endometrial smears. Our study showed that most of the ovarian cancer cases that had abnormalities in uterine cervical and endometrial cytologic tests exhibited progression of disease. As a consequence, our findings indicate that it is possible to predict development of ovarian cancer and its histologic type using cytology screening.
    Acta cytologica 01/2010; 54(4):575-81. DOI:10.1159/000325180 · 1.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Treatment of placenta increta often entails abdominal total hysterectomy. We present a case of placenta increta in which 3-dimensional computed tomography shows very high blood flow to the placenta, even after chemotherapy with methotrexate. Nonetheless, we were able to remove the region of the uterus that had been invaded by chorionic villi. Massive bleeding during the operation was prevented by ligation of the hypogastric artery and local injection of vasopressin. The combination of chemotherapy and partial resection of the uterus is quite a unique treatment for placenta increta patients. This approach enabled preservation of the uterus and the patient's fertility. We suggest this procedure could be one of the treatments for patients who have placenta increta and wish to retain their fertility.
    Gynecologic and Obstetric Investigation 11/2009; 69(2):112-5. DOI:10.1159/000262320 · 1.25 Impact Factor
  • M Matsuura · T Suzuki · M Morishita · R Tanaka · E Ito · T Saito
    [Show abstract] [Hide abstract]
    ABSTRACT: To determine optimal treatment for women with Stage IIIc endometrial carcinoma, extended-field radiotherapy (RT) plus chemotherapy (CT) was compared versus CT alone as adjuvant therapy. Twenty-nine patients with FIGO Stage IIIc endometrial cancer who underwent adjuvant treatment with 4.4 courses of CT (CAP or TC/DC) or 4.5 courses of CT (CAP or TC/DC) plus external pelvic RT (50 Gy) with paraaortic boost after surgery between 1992 and 2004 were retrospectively assessed. Fifteen patients underwent CT alone and 14 received combined treatment with CT/RT. Following treatment, the recurrence rate was 46.6% and 28.5% in the two treatment arms, respectively. There was a significant (p < 0.05) difference in the pelvic recurrence rate (33.3% and 7.1%, respectively). Combined treatment with RT/CT was associated with a better survival rate than CT alone (78% versus 62%, respectively). In Stage IIIc endometrial cancer, combined treatment with RT and CT reduces pelvic recurrence and improves progression-free survival and overall survival compared with CT alone.
    European journal of gynaecological oncology 02/2009; 30(1):40-4. · 0.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Treatment with opioid analgesics often causes adverse reactions that may make continuous use of such drugs difficult. We investigated the efficacy and safety of controlled-release oxycodone in the treatment of gynecologic cancer pain. The patients included 14 with cervical cancer, 6 with corpus cancer, and 17 with ovarian cancer. Treatment with controlled-release oxycodone was started at 5 mg/dose when pain control using nonsteroidal anti-inflammatory drugs became ineffective. The dose was titrated to the optimal level over a mean duration of 2.34 +/- 1.13 days, and the initially optimal dose was 18.92 +/- 5.23 mg/day. Although no patients experienced confusion, vomiting, or respiratory depression, 17 patients experienced adverse events, including constipation in 14 patients and nausea in 9 patients. The incidence of nausea was low in patients receiving oxycodone and prochlorperazine. In the present study, patients with moderate to severe pain caused by gynecologic cancer could successfully be treated with controlled-release oxycodone.
    American Journal of Therapeutics 01/2008; 15(1):31-5. DOI:10.1097/01.MJT.0000249928.97210.29 · 1.13 Impact Factor